A quarter of a century after AIDS became known as a frightening new disease, substantial progress has been attained on treatments that convert this once certain death sentence into a manageable chronic disease. While some prevention successes have been attained (e.g., screening of the blood supply in industrialized countries), a safe and effective vaccine-the "holy grail" of public health prevention-remains elusive.
In the late 1990s, the fi rst HIV vaccine taken to phase III trial, the VaxGen gp120 vaccine (VaxGen, Brisbane, CA, USA), became the basis for substantial debate and controversy between empiricists (generally public health persons who believed that the urgency of the pandemic required taking some risks, including a potentially low-effi cacy vaccine as a fi rst step) and reductionists (generally basic scientists and researchers who felt that the gp120 vaccine was unlikely to work given our state of knowledge and who wanted to wait for a better candidate vaccine). With trial results now available, we know that this vaccine was not effi cacious. We also know that a phase III trial, although challenging to organize and conduct among persons at high risk, is doable. What else we do and do not know scientifi cally is summarized nicely in the 19 chapters of this excellently edited, concise (150 pages), softbound book.
The book is organized into 5 parts: Global Overview; What Does a Vaccine Need to Do?; Preclinical Development: Design Challenges; Clinical Trials; and From Testing to Deployment. Each chapter, written by experts in each fi eld, is impressive in its balance of compactness (3-4 double-sided pages, including references), technical content, and user-friendliness (abstract and conclusion for each chapter make quick review easy).
The authors and editors are to be commended for bringing each of the key topics relevant to HIV vaccines to the reader in a highly accessible form. Key topics include HIV pathogenesis; the twists and turns of what specifi c knowledge of simian immunodeficiency virus and nonhuman primates is or is not applicable to HIV and humans; and the highly technical nature of modern immunology, virology, and structural biology. The editors were careful to include chapters on important nonscientifi c aspects of HIV vaccine development, such as clinical site development, regulatory issues, scaleup, and manufacturing.
This book provides an excellent introductory overview for the beginning HIV vaccine researcher or any person who needs a more technical primer on the various aspects of the HIV vaccine challenge. The number of HIV vaccine researchers is now increasing, given the support of several organizations (e.g., Bill and Melinda Gates Foundation) and collaborations (e.g., Global HIV Vaccine Enterprise, the Partnership for AIDS Vaccine Evaluation, and the Center for HIV-AIDS Vaccine Immunology). These organizations, collaborations, and researchers are attempting to better organize the human and technical resources needed to challenge this formidable foe on the scale of the Manhattan Project or the March of Dimes search for a polio vaccine. Let us hope that they will eventually succeed. 
A Country Story
Kenneth Fields "When I was a little girl back in East Texas," My mother's mother, Beulah, used to tell, "There was an outbreak of the German measles, Mama was pregnant, so I went away To a neighbor lady's, three or four miles from home When the fi rst signs showed. I was just eight, and sick, And lonesome for Mama. One day she came for me. My little sister had broken out, and Mama Figuring she would die, and the baby, too, Wanted us all together for those last weeks. She wanted me home with her. As it turned out My sister had been reading by the fi re And broke out from the heat, and it was me That carried the measles home. After Mama died I used to think of seeing her out the window Talking to the neighbor lady on that day, Crying and wiping her eyes with her apron hem."
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